An assay for measuring functional activated thrombin-activatable fibrinolysis inhibitor in plasma

Analytical Biochemistry

Volumn 372, Issue 1, 2008, Pages 32-40

  Kim, Paula Y G ^a   Foley, Jonathan ^a   Hsu, Grace ^a   Kim, Paul Y ^a   Nesheim, Michael E ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

Assay; CPU; Fibrinolysis; Plasma; TAFIa

Indexed keywords

AMINO ACIDS; ASSAYS; ENZYMES; FEEDBACK; FLUORESCENCE; PLASMAS; PROGRAM PROCESSORS; THERMODYNAMIC STABILITY;

FEEDBACK MECHANISMS; FIBRINOLYSIS; INTER-ASSAY VARIABILITY; LYSINE RESIDUES; NATURALLY OCCURRING; PLASMA CONCENTRATION; TAFIA; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR (TAFI);

PLASMA STABILITY;

FLUORESCEIN; LYSINE; PLASMINOGEN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

ARTICLE; ASSAY; BLOOD CLOT LYSIS; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; FLUORESCENCE; HUMAN; PRIORITY JOURNAL;

EID: 36048964941     PISSN: 00032697     EISSN: 10960309     Source Type: Journal    
DOI: 10.1016/j.ab.2007.09.034     Document Type: Article

References (30)

1. Bajzar L., Manuel R., and Nesheim M.E. Purification and characterization of TAFI, a thrombin activatable fibrinolysis inhibitor. J. Biol. Chem. 270 (1995) 14477-14484
2. Eaton D.L., Malloy B.E., Tsai S.P., Henzel W., and Drayna D. Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma. J. Biol. Chem. 266 (1991) 21833-21838
3. Bajzar L., Morser J., and Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J. Biol. Chem. 271 (1996) 16603-16608
4. Mao S.S., Cooper C.M., Wood T., Shafer J.A., and Gardell S.J. Characterization of plasmin-mediated activation of plasma procarboxypeptidase B: Modulation by glycosaminoglycans. J. Biol. Chem. 274 (1999) 35046-35052
5. Wang W., Boffa M.B., Bajzar L., Walker J.B., and Nesheim M.E. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J. Biol. Chem. 273 (1998) 27176-27181
6. Horrevoets A.J.G., Pannekoek H., and Nesheim M.E. Production and characterization of recombinant human plasminogen (S741C-fluorescein): A novel approach to study zymogen activation without generation of active protease. J. Biol. Chem. 272 (1997) 2176-2182
7. Hoylaerts M., Rijken D.C., Lijnen H.R., and Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator role of fibrin. J. Biol. Chem. 257 (1982) 2912-2919
8. de Vries C., Veerman H., and Pannekoek H. Identification of the domains of tissue-type plasminogen activator involved in the augmented binding to fibrin after limited digestion with plasmin. J. Biol. Chem. 264 (1989) 12604-12610
9. Suenson E., and Petersen L.C. Fibrin and plasminogen structures essential to stimulation of plasmin formation by tissue-type plasminogen activator. Biochim. Biophys. Acta 870 (1986) 510-519
10. Castellino F.J., and Powell J.R. Human plasminogen. Methods Enzymol. 80 (1981) 365-379
11. Walker J.B., and Nesheim M.E. A kinetic analysis of the tissue plasminogen activator and DSPAa1 cofactor activities of untreated and TAFIa-treated soluble fibrin degradation products of varying size. J. Biol. Chem. 276 (2001) 3138-3148
12. Schneider M., and Nesheim M. A study of the protection of plasmin from antiplasmin inhibition within an intact fibrin clot during the course of clot lysis. J. Biol. Chem. 279 (2004) 13333-13339
13. Boffa M.B., Wang W., Bajzar L., and Nesheim M.E. Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation thrombin/thrombomodulin-dependent activation thermal stability and enzymatic properties. J. Biol. Chem. 273 (1998) 2127-2135
14. Schneider M., Boffa M., Stewart R., Rahman M., Koschinsky M., and Nesheim M. Two naturally occurring variants of TAFI (Thr-325 and Il-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme. J. Biol. Chem. 277 (2002) 1021-1030
15. Willemse J., Leurs J., Verkerk R., and Hendriks D. Development of a fast kinetic method for the determination of carboxypeptidase U (TAFIa) using C-terminal arginine containing peptides as substrate. Anal. Biochem. 340 (2005) 106-112
16. Plummer Jr. T.H., and Kimmel M.T. An improved spectrophotometric assay for human plasma carboxypeptidase N. Anal. Biochem. 108 (1980) 348-353
17. Mock W.L., and Xu D. Catalytic activity of carboxypeptidase B and of carboxypeptidase Y with anisylazoformyl substrates. Bioorg. Med. Chem. Lett. 9 (1998) 187-192
18. Erdos E.G., and Sloane E.M. An enzyme in human blood plasma that inactivates bradykinin and kallidins. Biochem. Pharmacol. 11 (1962) 585-592
19. Mao S.S., Colussi D., Bailey C.M., Bosserman M., Burlein C., Gardell S.J., and Carroll S.S. Electrochemiluminescence assay for basic carboxypeptidases: Inhibition of basic carboxypeptidases and activation of thrombin-activatable fibrinolysis inhibitor. Anal. Biochem. 319 (2003) 159-170
20. Neill E.K., Stewart R.J., Schneider M.M., and Nesheim M.E. A functional assay for measuring activated thrombin-activatable fibrinolysis inhibitor in plasma. Anal. Biochem. 330 (2004) 332-341
21. van Tilburg N.H., Rosendaal F.R., and Bertina R.M. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 95 (2000) 2855-2859
22. Juhan-Vague I., Morange P.E., Aubert H., Henry M., Aillaud M.F., Alessi M.C., Samnegard A., Hawe E., Yudkin J., Margaglione M., Di Minno G., Hamsten A., and Humphries S.E. Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe. Arterioscler. Thromb. Vasc. Biol. 22 (2002) 867-873
23. Walker J.B., and Nesheim M.E. The molecular weights mass, distribution, chain composition, and structure of soluble fibrin degradation products released from a fibrin clot perfused with plasmin. J. Biol. Chem. 274 (1999) 5201-5212
24. Lundblad R.L., Kingdon H.S., and Mann K.G. Thrombin. Methods Enzymol. 45 (1976) 156-176
25. Bajzar L., Fredenburgh J.C., and Nesheim M.E. The activated protein C-mediated enhancement of tissue-type plasminogen activator-induced fibrinolysis in a cell-free system. J. Biol. Chem. 265 (1990) 16948-16954
26. Budzynski A.Z., and Stahl M. Partial reduction of bovine fibrinogen by some sulphydryl compounds. Biochim. Biophys. Acta 175 (1969) 282-289
27. Lijnen H.R. Elements of the fibrinolytic system. Ann. N.Y. Acad. Sci. 936 (2001) 226-236
28. Brouwers G.J., Vos H.L., Leebeek F.W.G., Bulk S., Schneider M., Boffa M., Koschinsky M., van Tilburg N.H., Nesheim M.E., Bertina R.M., Garci{dotless}́a E.B.G., novel A., and functional p. single nucleotide polymorphism in the coding region of the thrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels. Blood 98 (2001) 1992-1993
29. Marx P.F., Bouma B.N., and Meijers J.C.M. Role of zinc ions in activation and inactivation of thrombin-activatable fibrinolysis inhibitor. Biochemistry 41 (2002) 1211-1216
30. Giles A.R., Nesheim M.E., Herring S.W., Hoogendoorn H., Stump D.C., and Heldebrant C.M. The fibrinolytic potential of the normal primate following the generation of thrombin in vivo. Thromb. Haemost. 63 (1990) 476-481